HONG KONG, March 3, 2026 /PRNewswire/ -- PhotonPay, a leading global digital financial infrastructure platform, today announced a significant milestone in its global regulatory strategy. The company has officially obtained the Trust or Company Service Provider (TCSP) license from the Hong Kong Companies Registry, along with approvals from the Securities and Futures Commission (SFC) for Type 1 (Dealing in Securities), Type 4 (Advising on Securities), and Type 9 (Asset Management) licenses.
This regulatory milestone accelerates PhotonPay's mission to build a unified financial infrastructure for modern businesses. By integrating these new capabilities, PhotonPay is positioned to offer a more integrated financial solution, empowering global enterprises to manage treasury, hedge risk, and optimize capital alongside their global payment flows.
In the complex landscape of cross-border finance, compliance is the bedrock of scalability. The acquisition of the TCSP license (License No. TC010478) reflects PhotonPay's commitment to meeting the rigorous standards required to combat money laundering and terrorist financing in a premier financial hub.
For PhotonPay's clients, this translates to institutional-grade security. The license reinforces the company's risk management framework, ensuring strict protocols for corporate entity management and identity verification (KYC/KYB), effectively creating a secure moat for global capital operations.
While the TCSP license strengthens the defensive perimeter, the SFC Type 1, 4, and 9 licenses unlock new strategic capabilities.
This combination allows PhotonPay to transcend the boundaries of a traditional payments processor. By enabling securities trading, investment advisory, and asset management services, PhotonPay is building a "Payments + Asset Management" dual-engine ecosystem. This evolution means clients will soon be able to do more than just move funds—they will be equipped to put their idle capital to work through diverse wealth management and risk hedging tools.
"This is a milestone moment that transforms PhotonPay from a payments provider into a comprehensive financial partner," said Lewison Chen, Founder and CEO of PhotonPay. "With these licenses, we are building a one-stop financial infrastructure to support capital deployment, risk hedging, and wealth management. We are not just moving money; we are empowering international enterprises to maximize capital efficiency and secure robust growth in a complex global market."
About PhotonPay
Founded in 2015, PhotonPay is dedicated to building a digital financial infrastructure that connects the global economy. With compliance as a core pillar of its business, PhotonPay has established local teams in over ten major markets worldwide and has cultivated strategic partnerships with top-tier global financial institutions, including J.P. Morgan. PhotonPay continues to explore the integration of fintech with diverse business scenarios, empowering enterprises to achieve secure, compliant, and long-term growth in the international market.
*This material is for reference only and does not constitute any investment advice or offer. The relevant financial services will be provided by licensed entities in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Companies Registry, and are subject to applicable conditions. Please verify the latest licensing status through the official enquiry links (https://www.tcsp.cr.gov.hk/tcspls/?lang=en for TCSP license and https://apps.sfc.hk/publicregWeb/corp/BWJ859/details for SFC Type 1, 4, and 9 licenses).
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
From Payments to Wealth: PhotonPay Unlocks New Growth with Strategic Hong Kong Financial Licenses
|
NEW YORK, March 3, 2026 /PRNewswire/ -- IOPE, a clinical-grade skincare brand from Amorepacific and a leader in Korean anti-aging innovation, officially debuts in the U.S. market today. Backed by 30 years of research and expertise in Korea, the United States marks the brand's second global market through strategic retail partnerships at Sephora. IOPE launches on Sephora.com today, rolling out to Sephora stores later in the month.
"We are thrilled to bring IOPE to the U.S. after decades of unparallelled performance in Korea," said Giovanni Valentini, CEO Amorepacific North America. "Consumers are more discerning than ever, prioritizing clinically proven efficacy and visible results in an increasingly saturated skincare market. With IOPE, we are introducing targeted skincare solutions, that are clinically tested, at a competitive price point."
For three decades, IOPE has been at the forefront of Korean anti-aging research, grounded in rigorous clinical testing. The brand has pioneered advancements in key active ingredients, including PDRN, stabilized Vitamin C, and innovative retinol stabilization technology that is supported by 26 Korean patents and more than a dozen scientific publications. As Korean skincare continues to set the global standard for innovation and performance, IOPE stands among the category's most respected leaders.
IOPE's professional treatment–inspired formulations are rooted in evidence-based research and designed to deliver visible improvements across key skin concerns, including texture, firmness, brightness, and overall vitality, redefining expectations for at-home skincare performance.
IOPE enters the U.S. market with nine targeted products, featuring the brand's transformative XMD, Retinol RX™, Vitamin C, and PDRN Caffeine collections. Their newest innovations draw inspiration from Korea's viral skin booster treatments and are clinically proven to deliver professional treatment-level results at home:
- XMD Stem III Clinical Recovery Serum ($59): Inspired by Korea's viral professional PDRN treatments, this advanced serum was clinically tested to deliver professional PDRN treatment–level results across six key metrics, including increased volume, improved elasticity, and enhanced texture – without the downtime or discomfort associated with in-office treatments. The breakthrough formula is powered by 92.3% PDRN H.A.™ Liposome Complex, featuring PDRN, micro-molecular hyaluronic acid, and a soothing allantoin-based complex.
- Retinol RX™ 2% Reti-jection™ Serum ($57): Formulated with a 2% concentration of Retinol RX™ – IOPE's proprietary retinoid complex – this high-performance serum is designed to optimize efficacy while reducing irritation. The formula features retinol-infused spicules to enhance absorption. The serum is clinically proven to deliver collagen booster treatment–level results, including reduced look of wrinkles, minimized pore appearance, and enhanced radiance.
IOPE products range in price from $6.50 for a single sheet mask to $69 for XMD Stem III Clinical Recovery Cream.
IOPE is available now at Sephora.com and will be available in Sephora stores nationwide starting March 13, 2026.
About AMOREPACIFIC:
Established in 1945, Amorepacific is Korea's leading beauty company, powered by a global portfolio of category defining skincare, makeup, haircare, and wellness brands. Rooted in pioneering research that began with Korea's first cosmetics lab, the company continues to shape the future of K-beauty through bio-driven, longevity-focused innovation.
NEW YORK, March 3, 2026 /PRNewswire/ -- IOPE, a clinical-grade skincare brand from Amorepacific and a leader in Korean anti-aging innovation, officially debuts in the U.S. market today. Backed by 30 years of research and expertise in Korea, the United States marks the brand's second global market through strategic retail partnerships at Sephora. IOPE launches on Sephora.com today, rolling out to Sephora stores later in the month.
"We are thrilled to bring IOPE to the U.S. after decades of unparallelled performance in Korea," said Giovanni Valentini, CEO Amorepacific North America. "Consumers are more discerning than ever, prioritizing clinically proven efficacy and visible results in an increasingly saturated skincare market. With IOPE, we are introducing targeted skincare solutions, that are clinically tested, at a competitive price point."
For three decades, IOPE has been at the forefront of Korean anti-aging research, grounded in rigorous clinical testing. The brand has pioneered advancements in key active ingredients, including PDRN, stabilized Vitamin C, and innovative retinol stabilization technology that is supported by 26 Korean patents and more than a dozen scientific publications. As Korean skincare continues to set the global standard for innovation and performance, IOPE stands among the category's most respected leaders.
IOPE's professional treatment–inspired formulations are rooted in evidence-based research and designed to deliver visible improvements across key skin concerns, including texture, firmness, brightness, and overall vitality, redefining expectations for at-home skincare performance.
IOPE enters the U.S. market with nine targeted products, featuring the brand's transformative XMD, Retinol RX™, Vitamin C, and PDRN Caffeine collections. Their newest innovations draw inspiration from Korea's viral skin booster treatments and are clinically proven to deliver professional treatment-level results at home:
- XMD Stem III Clinical Recovery Serum ($59): Inspired by Korea's viral professional PDRN treatments, this advanced serum was clinically tested to deliver professional PDRN treatment–level results across six key metrics, including increased volume, improved elasticity, and enhanced texture – without the downtime or discomfort associated with in-office treatments. The breakthrough formula is powered by 92.3% PDRN H.A.™ Liposome Complex, featuring PDRN, micro-molecular hyaluronic acid, and a soothing allantoin-based complex.
- Retinol RX™ 2% Reti-jection™ Serum ($57): Formulated with a 2% concentration of Retinol RX™ – IOPE's proprietary retinoid complex – this high-performance serum is designed to optimize efficacy while reducing irritation. The formula features retinol-infused spicules to enhance absorption. The serum is clinically proven to deliver collagen booster treatment–level results, including reduced look of wrinkles, minimized pore appearance, and enhanced radiance.
IOPE products range in price from $6.50 for a single sheet mask to $69 for XMD Stem III Clinical Recovery Cream.
IOPE is available now at Sephora.com and will be available in Sephora stores nationwide starting March 13, 2026.
About AMOREPACIFIC:
Established in 1945, Amorepacific is Korea's leading beauty company, powered by a global portfolio of category defining skincare, makeup, haircare, and wellness brands. Rooted in pioneering research that began with Korea's first cosmetics lab, the company continues to shape the future of K-beauty through bio-driven, longevity-focused innovation.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
IOPE LAUNCHES IN THE U.S.
